INCYTE DL-,001 | 69.74 / +0.11% |
Date/Time | 05/21 / 12:59 |
Chg. / Chg.(%) | 0.08 / +0.11% |
Bid | 69.74 |
Ask | 71.15 |
Open | 69.74 |
Previous Close | 69.66 |
High | 69.74 |
Low | 69.46 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 72 |
ISIN | US45337C1027 |
Security | ICY |
Exchange | Lang & Schwarz |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 69.74 | ![]() |
|
NASDAQ | 74.8800 | ![]() |
1,291,332 |
IEX | 74.87 | ![]() |
73,723 |
Cboe US | 74.90 | ![]() |
42,197 |
TradeGate | 70.820 | ![]() |
1,473 |
Hannover | 70.30 | ![]() |
0 |
Frankfurt | 70.2300 | ![]() |
0 |
München | 70.37 | ![]() |
0 |
Düsseldorf | 69.46 | ![]() |
0 |
Berlin | 70.71 | ![]() |
0 |
Stuttgart | 70.570 | ![]() |
0 |
London Domes.. | 74.92 | ![]() |
|
Quotrix | 70.6500 | ![]() |
|
gettex | 70.660 | ![]() |
|
Mexico | 1,492.00 | ![]() |
9 |
News
- RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
03/23/2022 / 21:01 - GlobeNewswire - STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations
03/14/2022 / 21:05 - GlobeNewswire - Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
03/01/2022 / 13:55 - GlobeNewswire - Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
02/28/2022 / 22:36 - GlobeNewswire - MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
02/24/2022 / 22:01 - GlobeNewswire